Bitko Vira, Barik Sailen
Department of Biochemistry and Molecular Biology, University of South Alabama, College of Medicine, MSB 2370, 307 University Blvd., Mobile, AL 36688-0002, USA.
Drug Discov Today Ther Strateg. 2007;4(4):273-276. doi: 10.1016/j.ddstr.2008.01.001.
This review summarizes recent experimental achievements in the area of the development of new RNA interference (RNAi) therapeutics for the treatment of viral respiratory diseases. Delivery of siRNA to their intended target tissue remains the biggest problem for most therapeutic applications of these compounds. Appropriate formulations and chemical modifications for improved stability will boost the probability of utilization of RNAi drugs in the clinical applications.
本综述总结了用于治疗病毒性呼吸道疾病的新型RNA干扰（RNAi）疗法开发领域的近期实验成果。对于这些化合物的大多数治疗应用而言，将小干扰RNA（siRNA）递送至其预期的靶组织仍然是最大的问题。合适的制剂和化学修饰以提高稳定性将增加RNAi药物在临床应用中的使用可能性。
